A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: The PIVOT trial

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 47, Issue 4, 2007, Pages 279-285

  Hennessy, Annemarie ^a,d,e   Thornton, Charlene E ^a   Makris, Angela ^b   Ogle, Robert F ^a   Henderson Smart, David J ^c   Gillin, Adrian G ^a   Child, Andrew ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c New South Wales Pregnancy and Newborn Services Network   (Australia)

^d HEART RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Diazoxide; Hydralazine; Hypertensivecrisis; Pre eclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; DIAZOXIDE; HYDRALAZINE; LABETALOL;

ARTICLE; AUSTRALIA; BLOOD PRESSURE REGULATION; BOLUS INJECTION; CESAREAN SECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMERGENCY TREATMENT; FEMALE; FLUSHING; HUMAN; HYPOTENSION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PERINATAL PERIOD; PREECLAMPSIA; PRENATAL PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIOTOCOGRAPHY; CESAREAN SECTION; DIAZOXIDE; FEMALE; HUMANS; HYDRALAZINE; HYPERTENSION, PREGNANCY-INDUCED; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; PREGNANCY; TREATMENT OUTCOME;

EID: 34447506186     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2007.00738.x     Document Type: Article

References (34)

1. Waterstone M, Bewley S. Incidence and predictors of severe obstetric morbidity: Case control-study. BMJ 2001; 322: 1089-1093.
2. Martin J, Thigpen BO, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: A paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105: 246-254.
3. The Magpie Trial Collaborative Group. Do women with pre-eclampsia and their babies benefit from magnesium sulphate? The magpie trial: A randomised placebo-controlled trial. Lancet 2002; 359: 1877-1890.
4. Rudnicki M, Frolich A, Pilsgaard K et.al. Comparison of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension. Gynecol Obstet Invest 2000; 49: 231-235.
5. Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J 1987; 71: 354-356.
6. Harper A, Murnaghan GA. Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynecol 1991; 98: 453-459.
7. Michael CA. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. Aust N Z J Obstet Gynaecol 1986; 26: 26-29.
8. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszon P. Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis. BMJ 2003; 327: 955-957.
9. Dudley DK. Minibolus diazoxide in the management of severe hypertension in pregnancy. Am J Obstet Gynecol 1985; 151: 196-200.
10. Xu B, Makris A, Thornton C, Ogle R, Horvath JS, Hennessy A. Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens 2006; 25: 915-922.
11. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. [Systematic Review]Cochrane Pregnancy and Childbirth Group Cochrane Database Syst Rev 2006; 3.
12. Perinatal Society of Australia and New Zealand. Sydney Impact Clinical Trial Registry. [Updated 2005, cited 2005 December 5.]Available from: http://www.ctc.usyd.edu.au/6registry/impacthome.htm.
13. Brown MA, Hague W, Higgins J et.al. The Detection, investigation and management of hypertension in pregnancy: Executive summary. Aust N Z J Obstet Gynaecol 2000; 40: 133-138.
14. Patel H, Beeby PJ, Henderson-Smart DJ. Predicting the need for ventilatory support in neonates 30-36 weeks' gestational age. J Paediatr Child Health 2003; 39: 206-209.
15. East CE, Brennecke SP, King JF, Chan FY, Colditz PB, on behalf of the FOREMOST Study Group. The effect of intrapartum fetal pulse oximetry, in the presence of a non-reassuring fetal heart rate pattern, on operative delivery rates for non-reassuring fetal status: A multicenter, randomized controlled trial (the FOREMOST trial). Am J Obstet Gynecol 2006; 194: 606, e1-16.
16. Royal Prince Alfred Hospital. Annual Obstetrics Report 2003. Sydney: CSAHS Printing, 2004.
17. Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987; 70: 328-333.
18. Bhorat IE, Naidoo DP, Rout CC, Moodley J. Malignant ventricular arrhythmias in eclampsia: A comparison of labetalol with dihydralazine. Am J Obstet Gynecol 1993; 168: 1292-1296.
19. Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin Exp Hypertens 1982; B1: 371-383.
20. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT et.al. Severe hypertension in pregnancy: Hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006; 128: 157-162.
21. Aali B, Nejad S. Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstet Gynecol Scand 2002; 81: 25-30.
22. Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991; 77: 331-337.
23. Kwawukume EY, Ghosh TS. Oral nifedipine therapy in the management of severe preeclampsia. Int J Gynaecol Obstet 1995; 49: 265-269.
24. Martins-Costa S, Ramos JG, Barros E, Bruno RM, Costa CA, Goldin JR. Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension. Clin Exper Hypertens Preg 1992; B11: 25-44.
25. Maharaj B, Moodley J, Khedun SM, van der Byl K, Madhanpall N. Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: A pilot study. Blood Press Suppl 1994; 1: 54-56.
26. Duggan PM, McCowan LM, Stewart AW. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. Aust N Z J Obstet Gynaecol 1992; 32: 335-338.
27. Seabe SJ, Moodley J, Becker P. Nifedipine in acute hypertensive emergencies in pregnancy. S Afr Med J 1989; 76: 248-250.
28. Jegasothy R, Paranthaman S. Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: Potential for use in rural practice. J Obstet Gynaecol Res 1996; 22: 21-24.
29. Wacker J, Lewicka S, Haack D, Bastert G. Hypertension in pregnancy. J Steroid Biochem Mol Biol 1993; 45: 65-68.
30. Howarth GR, Seris A, Venter C, Pattinson RC. A randomized controlled pilot study comparing urapidil to dihydralazine in the management of severe hypertension in pregnancy. Hypertens Preg 1997; 16: 213-221.
31. Moodley J, Gouws E. A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. Br J Obstet Gynaecol 1992; 99: 727-730.
32. Bolte AC, van Eyck J, Kanhai HH, Bruinse HW, van Geijn HP, Dekker GA. Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: Maternal outcome. Am J Obstet Gynecol 1999; 180: 371-377.
33. Steyn DW, Odendaal HJ. Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. Eur J Obstet Gynecol Reprod Biol 1997; 75: 155-159.
34. Rossouw HJ, Howarth G, Odendaal HJ. Ketanserin and hydralazine in hypertension in pregnancy -A randomised double-blind trial. S Afr Med J 1995; 85: 525-528.